top of page
Asset 1@3x.png

Pioneering the development of novel immunotherapies for patients with blood cancers and B-cell disorders.

News & Events

HaemaLogiX's CMDO, Tertia Dex at the Women in BIO and Health – Industry and Networking Forum

HaemaLogiX's CMDO, Tertia Dex to speak at the Women in BIO and Health – Industry and Networking Forum

5 May 2024
On Rare Disease Day, we reflect on the courage and resilience of those facing the challenges of rare medical conditions.

Honouring Rare Disease Day: The Battle Against Multiple Myeloma and AL Amyloidosis

28 February 2024
HaemaLogiX Ltd, a clinical stage biotech, is pleased to announce the appointment of Laurence Turka, M.D. to its board as a non-executive director.

HaemaLogiX announces appointment of Laurence Turka, M.D. as a Non-Executive Director

31 January 2024

Our Team

The HaemaLogiX management team has deep expertise in immunotherapy development and the unique antigens that our treatments target. Our Scientific Advisory Board comprises internationally recognised experts in monoclonal antibodies and haematology. 

Asset3@3x.png
Asset 4@3x.png

Our Pipeline

We’re developing a suite of diverse immunotherapies including monoclonal antibodies, CAR-T cells and bispecific antibodies, with a key focus on treating multiple myeloma and early investigation of AL Amyloidosis. 

Our Innovation

Our immunotherapies are designed to target and attack two unique antigens expressed on malignant cells – these antigens are not found on normal cells or tissues - making our treatments unlike others on the market. 

car-t ell.png
bottom of page